Rationale: Matrix metalloproteinase-1 (MMP-1) and mast cells are present in the airways of people with asthma.
and abnormal lung function in adulthood (5, 6) . Changes observed in airway remodeling include epithelial desquamation, goblet cell hyperplasia, reticular basement membrane thickening, increased airway smooth muscle (ASM) mass, and abnormal extracellular matrix (ECM) deposition (1, 7) . Airway remodeling has been seen as a consequence of inflammation, although airway contraction, in the absence of inflammation, can also drive aspects of remodeling (8) . Because airway structural changes may support inflammation (9) it is likely that airway inflammation, bronchoconstriction, remodeling, and fixed airflow obstruction interact in a linear, parallel, or combined manner to drive the asthma phenotype.
Mast cells, particularly activated, degranulated forms, are more common within ASM bundles of those with asthma (10) (11) (12) and generate proinflammatory cytokines including IL-4, IL-5, and IL-13, which regulate IgE production, eosinophilic inflammation, and profibrogenic cytokines, including transforming growth factor-b and basic fibroblast growth factor-2. Preformed serine proteases including tryptase, chymase, and carboxy-peptidase are secreted from granules and interact with various cell types via proteolytically activated receptors (PARs) (11) . Collectively, mast cell mediators contribute to airway inflammation, hyperresponsiveness and remodeling causing bronchoconstriction, ASM cell proliferation, and inflammatory cell recruitment (13) .
Our overarching hypothesis is that the airway environment in asthma sustains airway remodeling (14) (15) (16) . We have shown that components of the ECM in asthmatic airways can promote remodeling by affecting proliferation (17) , migration (16) , apoptosis (18) , matrix metalloproteinase (MMP) activation (16) , and b-agonist signaling of ASM cells (19) . Here we hypothesized that mast cell proteases are responsible for MMP-1 activation in asthma and used a combination of in vitro and human studies to examine the interactions between mast cells, MMP-1, airway remodeling, and asthma symptoms. Some of this work has previously been presented as abstracts (20, 21) .
Methods

Patients and Control Subjects
Two asthma cohorts with matched control groups were studied. All subjects gave written informed consent. The relationship between ASM growth and MMP-1 expression was examined in 16 subjects with mild or moderate asthma, defined by the Global Initiative for Asthma criteria (22) , without a history of exacerbation, change in therapy, or use of oral steroids for at least 6 weeks and 11 nonsmoking, age-matched control subjects without lung disease. Further study details are included in the online supplement. Those with asthma underwent spirometry, bronchial provocation testing, and modified Juniper Asthma Control Questionnaire (23) . All subjects underwent flexible bronchoscopy with bronchial washings and biopsies taken from the right bronchus intermedius. The study was approved by the Nottingham Research Ethics Committee (12/EM/0199). The relationship between asthma exacerbations and MMP-1 activation was examined in a second group of 11 subjects with mild and 17 with moderate asthma with exacerbations induced by rhinovirus inoculation compared with 11 healthy control subjects. The study has been described in detail previously (24) . Briefly, nonsmokers with mild or moderate asthma, defined by Global Initiative for Asthma criteria, and nonsmoking, nonatopic healthy volunteers without a recent viral illness or asthma exacerbation, were recruited. Symptom scores, lung function, bronchoscopy, and bronchoalveolar lavage (BAL) were performed 2 to 4 weeks before inoculation with rhinovirus 16. Following virus inoculation, symptom scores were recorded daily and lung function, bronchoscopy, and BAL were repeated after 4 days. The study was approved by the St Mary's Hospital ethics committee (09/H0712/59).
Cells and Tissues
Bronchial biopsy tissue was either processed for immunohistochemistry or used for culture of ASM cells as previously described with cells used at passage five or less (see Figure E1 in the online supplement) (15) .
Mast cell supernatants were prepared from HMC-1 mast cells activated using phorbol 12-myristate 13-acetate (50 ng/ml) and calcium ionophore (A23187; 25 ng/ml) for 16 hours. Control mast cell supernatants had phorbol 12-myristate 13-acetate and calcium ionophore added after removal of the cell pellet. Inhibition of proteases was performed by preincubation of supernatants with protease inhibitors used at the manufacturer's recommended concentrations. Full details are included in the online supplement.
MMP-1 Assays
Total MMP-1 protein (including pro and active species) and TIMP1 were measured using Duoset ELISAs (R&D Systems, Abingdon, UK). MMP-1 activity was measured using a Human Active MMP-1 Fluorokine E Kit (R&D Systems). Generation of the active 43-kD MMP-1 species was assessed by Western blotting (14) . Proteolytic cleavage of MMP-1 by tryptase was examined by incubation of recombinant pro-MMP-1 (10 ng; R&D Systems) and recombinant human mast cell tryptase (0.1-2 IU; Promega, Southampton, UK) in physiologic buffered saline for 30 minutes at 37 8 C. Products were resolved on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and visualized by silver staining.
ECM Preparations
ASM cell-derived ECM was prepared as described (14) . Further details are given in the online supplement.
In Vitro Cell Proliferation, Adhesion, and Apoptosis Assays Cell proliferation was determined by both 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay and cell counting as described (16) with ASM cultured on ECM preparations for 48 hours in the presence of 1% fetal bovine serum. For adhesion assays, fluorescently labeled ASM cells were seeded onto ECM preparations and adherent cells measured by fluorescence over 2-18 hours. Apoptosis was assessed using an In Situ Cell Death Detection kit, AP (Roche, West Sussex, UK). Full details are provided in the online supplement.
MMP-1 siRNA Knockdown siRNA was used as previously described (14) and reduced MMP-1 protein by greater than 70% (see Figure E2 ).
Quantification of Airway Mast Cells and Proliferating ASM Cells
Endobronchial biopsies were immunostained as previously described (15) with images captured using a Digital Nanozoomer (Hamamatsu Photonics UK Ltd., Welwyn Garden City, UK). All slides were assessed by a respiratory pathologist (I.S.). ASM bundles were identified by immunostaining with anti a-smooth muscle actin (Roche) and ASM cell nuclei counted using DAPI staining. In adjacent 
Results
MMP-1 Is Expressed in the Airways of Patients with Asthma
Details of the 16 patients and 11 control subjects in the airway remodeling study are shown in Table 1 . The expression of total MMP-1 protein (ELISA) was 5.4-fold greater in bronchial washings from patients with asthma than those from control subjects (control: mean, 0.14 ng/ml; 95% confidence interval [CI], 0.095-0.197; asthma: mean, 0.79 ng/ml; 95% CI, 0.35-1.21; P = 0.002) ( Figure 1A ). Western blotting of these samples identified a single 54-kD band consistent with pro-MMP-1 in those with asthma but not in healthy control subjects. The 43-kD active MMP-1 species was not detected in either group ( Figure 1B ). In keeping with the Western blot analysis, MMP-1 activity was not detected in control subjects and barely present in those with stable asthma ( Figure 1C ). ASM cells were cultured from endobronchial biopsies of six of these patients with asthma and six healthy control subjects. Total MMP-1 protein was 3.3-fold higher in ASM culture supernatants from those with asthma than from healthy control subjects (control: mean, 0.48 ng/ml; 95% CI, 0.23-0.74; asthma: mean, 1.57 ng/ml; 95% CI, 0.30-1.23; P = 0.002) ( Figure 1D ). the supernatants of activated or nonactivated HMC-1 mast cells. Activated, but not control, mast cell supernatants resulted in the appearance of the active 43-kD MMP-1 species, which could be inhibited using a pan protease inhibitor (Figure 2A ). To determine which protease was responsible for MMP-1 activation, we used more specific protease inhibitors. Generation of active MMP-1, detected by Western blotting, was blocked by panserine protease and specific tryptase inhibitors, but not a chymase inhibitor ( Figures 2B and 2C ). The generation of active MMP-1 was associated with an increase in MMP-1 activity (see Figure E3 ). To determine if mast cell tryptase activated MMP-1 by direct cleavage, we coincubated recombinant mast cell tryptase and pro-MMP-1.
Increasing concentrations of mast cell tryptase were associated with production of a cleaved MMP-1 protein at 43 kD consistent with active MMP-1 ( Figure 2D ).
Activated Mast Cell Treatment of ASM Cells Generates a Proproliferative ECM
To determine if MMP-1 activation would lead to proteolytic modification of ASM cellderived ECM and promote ASM growth, we generated ASM-derived ECM preparations from patients with asthma and control subjects following treatment with activated or control mast cell supernatants. ASM cells were then seeded onto these preparations and cell proliferation measured in the presence of 1% serum. To determine if the proproliferative matrix generated by activated mast cells was dependent on mast cell tryptase activation of MMP-1, mast cell supernatants were incubated with a range of protease inhibitors before treatment of ASM cells. The excess ASM proliferation, estimated by MTT reduction, induced by activated mast cells, was blocked by a pan protease inhibitor and inhibitors of serine proteases, metalloproteinases, and tryptase but not chymase ( Figure 4A ). We then treated ASM with siRNA targeting MMP-1 or control siRNA during ECM deposition to confirm that MMP-1 was the responsible protease. Knockdown of MMP-1 but not control siRNA blocked the excess proliferation generated by activated mast cell supernatants estimated by MTT reduction ( Figure 4B ). Furthermore, direct application of activated MMP-1 (10 ng/ml) to untreated ASM-derived matrix significantly enhanced the proliferative capacity of both asthma and control-derived matrix, whereas activated and control mast cell supernatants, in the absence of ASM cells, had no effect ( Figure 4C ).
Relationship between MMP-1 Activation and Asthma Exacerbations
To understand the relevance of these in vitro findings to human asthma, we examined MMP-1 activation in BAL fluid of patients with asthma who developed exacerbations in response to rhinovirus inoculation. After virus inoculation, lower respiratory symptom scores increased and more severe reductions in lung function were observed in the subjects with asthma as previously reported (24) . After viral inoculation, mean MMP-1 activity increased 3.9-fold (n = 28; difference, 0.445; 95% CI of difference, 0.052-0.84; P = 0.03) in patients with asthma and 11-fold in healthy control subjects, although the latter was not significant (n = 11; difference, 0.14; 95% CI of difference, 20.025 to 0.53) ( Figure 5 ). Importantly, the degree of MMP-1 activation after exacerbation in those with asthma was strongly correlated with more severe falls in FEV 1 (r 2 = 0.54; P , 0.0001) and peak lower respiratory symptom score severity (r 2 = 0.24; P = 0.007) ( Figure 6 ). BAL TIMP1 protein was similar in control subjects and those with asthma and did not change significantly in response to viral challenge (see Figures E8 and E9 ).
Association between ASM Proliferation and Mast Cells in Asthma
Having shown that mast cell tryptase dependent MMP-1 activation leads to proproliferative ECM remodeling in vitro, we examined the association between tryptase-positive mast cells and ASM proliferation in human airways. We quantitated proliferating ASM cells and tryptase-positive mast cells in the ASM bundles of the first group of 16 patients with asthma and 11 healthy control subjects ( Figure 7A ). Bronchial biopsies contained ASM in 12 and 10 cases, respectively. In these samples, both proliferating ASM cells and tryptasepositive mast cells tended to be more common in those with than without asthma, although the differences between groups were not significant ( Figure 7B ). Across individuals, the number of proliferating ASM cells was positively correlated with mast cell infiltration in both those with and without asthma (r 2 = 0.49; P , 0.0001) ( Figure 7C ).
MMP-1 Levels Are Associated with Bronchial Reactivity in Stable Asthma
Because collagenase expression and MMP-1 activity have been related to airway contraction in vitro (25, 26) we examined the relationship between airway MMP-1 expression and airway contraction induced by methacholine in the first group of 16 patients with asthma. Increasing airway responsiveness to methacholine was associated with increasing total airway MMP-1 levels (r 2 = 0.256; P = 0.04) ( Figure 8A ). In these stable patients, Juniper Asthma Control Questionnaire scores were not associated with total MMP-1 level (r 2 = 0.09; P = 0.23) ( Figure 8B ).
Discussion
MMP-1 and mast cells are minimally present in normal airways but both are present in the ASM bundles of patients with asthma (27, 28) . Here we have identified a potential mechanism linking MMP-1 activation by airway mast cells with ECM remodeling, ASM growth, airway contraction, and asthma severity. We have shown that MMP-1 is directly activated by mast cell tryptase and that this activation remodels ECM to generate a proproliferative substrate for ASM cells. In patients with stable asthma, the presence of tryptase-positive mast cells is associated with enhanced ASM proliferation and MMP-1 expression is directly correlated with airway narrowing in response to bronchoconstrictor stimuli. During exacerbations, MMP-1 activation is associated with exacerbation severity. These findings suggest that the interaction between MMP-1, mast cells, and ECM remodeling may contribute to airway contraction, remodeling, and worsening symptoms in patients with asthma.
Enhanced expression of MMP-1 has been described in response to several mediators associated with asthma and airway remodeling including collagen, tenascin, cyclical strain, leukotriene D4, tumor necrosis factor-a, and plateletderived growth factor (27, (29) (30) (31) (32) , although the significance of this in asthma is unknown. In common with other MMPs, proteolytic removal of the prodomain is required for MMP-1 activation. Although MMP-1 activation by serine proteases has been described previously (33) , in our study we demonstrated by direct interaction of the two proteins, that mast cell tryptase cleaves the prodomain of MMP-1 in vitro and supernatants from activated (degranulated) mast cells activate MMP-1. MMP-1 cleaves triple helical fibrillar collagens including collagens 1, 2, 3, 7, 8, and 10 and gelatin as part of ECM turnover, but can also generate bioactive mediators by collagen processing including the neutrophil chemoattractant matrikine Pro-Gly-Pro (34) . In addition to collagens, MMP-1 has other matrix substrates including aggrecan, proteoglycan, versican, and perlecan (35) and can activate or inactivate bioactive proteins including insulin-dependent growth factor binding proteins 2, 3, and 5; PAR 1; CXCL8; and CXCL12 (36) . The advantage of using biosynthesized ASM matrix in our study is the presence of multiple protein substrates in the preparation, making this system more physiologic than individual ECM
substrates. This does mean we are unable to define which ECM-related proteins have been proteolytically processed and are responsible for the effect. It is likely that bioactive neoepitope generation, or ECMassociated growth factor processing, alters signaling to ASM (37) . Our findings do show there is an absolute requirement for ASM cell-derived MMP-1 in generation of the proproliferative ECM by tryptase and that the direct action of mast cell-derived proteases is not sufficient to generate proliferative ECM in the absence of ASMderived MMP-1. Although we cannot directly link the ECM remodeling by MMP-1 and ASM growth seen in vitro to humans with asthma and airway MMP-1 may not completely reflect ASM-derived MMP-1: our findings, using primary asthmaderived ASM cells, are consistent with this mechanism acting in asthma.
Tryptase-mediated activation of MMP-1 is one pathway by which mast cells could contribute to airway remodeling. Mast cells and mast cell degranulation are associated with severe asthma. In vivo it is likely that other mast cell mediators including prostaglandins and tryptase, by activation of PAR2, as previously observed in vitro, may stimulate ASM proliferation and contraction to worsen asthma symptoms (38, 39) . We have previously shown that MMP-1 also supports ASM contraction in vitro and others have shown enhanced contraction of collagenase-treated bronchial rings (14, 40) . In patients with stable asthma we found that airway MMP-1 is associated with airway narrowing in response to methacholine and that during exacerbations, activation of MMP-1 is associated with exacerbation severity judged by increasing symptoms and fall in FEV 1 . The mechanisms of airway narrowing and the relationship between airway remodeling, airway contraction, and BHR are complex. Our findings, and those of others linking alterations in the ECM to ASM growth (18) , contraction (19) , and ASM mass with BHR (41), could be consistent with MMP-1 activity contributing to changes in cell/matrix coupling and ECM stiffness altering resistive ASM loading to result in increased airway narrowing (42) (Figure 9 ).
Longitudinal studies are generally consistent with the presence, but not progression, of airway obstruction with the minority of studies suggesting airflow obstruction increases with disease duration (2) . No longitudinal studies have examined ASM or number or ECM mass over time in those with asthma and there are conflicting data on rates of ASM proliferation in asthma (5, 6, 43) . Some suggest ASM proliferation is not elevated in patients with asthma (44) , whereas others have demonstrated that ASM proliferation in bronchial biopsies is both enhanced in asthma and related to asthma severity (45) . These contradictory findings both in vitro and in vivo may relate to a combination of methodologic and study population differences. Our findings, showing no difference in ASM proliferation in situ between those with asthma and control subjects overall, may reflect the exclusion of those with severe asthma. Importantly, using a mast cell number we observe an association with ASM proliferation. This suggests specific aspects of the asthma phenotype drive ASM proliferation, rather than enhanced ASM proliferation being a feature of all with asthma at all times in their disease. Structural changes in the airway are the net result of many processes including both ASM proliferation and death, ECM deposition, and resorption. The association of ASM growth and mast cells in vitro and in vivo is consistent with the generation of an environment that would alter this balance to sustain airway remodeling in the asthmatic airway (46) . Importantly, our findings suggest a mechanism driving asthma severity that is largely independent of Th2-mediated inflammation and are of relevance to developing therapies for the less well understood Th2-low asthma endotype, which is poorly responsive to current treatments (47) . For most of those with asthma, airway remodeling is not completely preventable with current asthma treatments and alternatives are required to target this complication of chronic asthma. Inhibition of MMPs in humans has failed as a therapeutic strategy because of the poor specificity of MMP inhibitors and effects caused by MMPs having multiple effects on beneficial and injurious processes. Targeting the mast cell/smooth muscle interaction may be a potential option to prevent MMP-1-mediated airway remodeling in patients with asthma. Recently, Hinks and coworkers (48) Figure 9 . Summary of findings and hypothesis. The airway phenotype of those with asthma differs from normal in many respects, including increased mast cell numbers and pro-matrix metalloproteinase (MMP)-1 expression. Exacerbations, other inflammatory stimuli, and possibly contraction cause mast cell degranulation, tryptase release, and MMP-1 activation. Active MMP-1 causes extracellular matrix processing to support airway smooth muscle proliferation. These changes result in fixed airflow obstruction, increased bronchial hyperresponsiveness, airway contraction, and worsening asthma symptoms. Interactions between airway remodeling, bronchial hyperresponsiveness, and airway contraction act at multiple levels, leading to worsening asthma symptoms. ASM = airway smooth muscle; BHR = bronchial hyperresponsiveness; ECM = extracellular matrix.
of this pathway in specific asthma endotypes. In summary we have shown that tryptase-dependent MMP-1 activation can remodel the ECM to support ASM proliferation. In the airways of patients with asthma, tryptase-positive mast cells are colocalized with proliferating ASM cells and MMP-1 expression is associated with BHR and MMP-1 activation with asthma exacerbations and exacerbation severity. Disrupting mast cell/ASM interactions may be a potential therapeutic option against airway remodeling. n Author disclosures are available with the text of this article at www.atsjournals.org.
